细胞信息
发货规格	1×10⁶
别名	CCRF/CEM， CCRFCEM， CCRF.CEM， CCRF CEM， CCRF， CEM， CEM-CCRF， CEM-CCRF (CAMR)， CCRF/CEM/0， CEM/0， CEM-0， CCRF-CEM/S， GM03671， GM03671C
形态	淋巴母细胞样
生长特性	悬浮
培养条件	RPMI-1640+10%FBS+1%P/S
冻存条件	90%FBS+10%DMSO
传代方式	离心
倍增时间	24~30h
传代比例	维持细胞浓度在1x105~1x106个/ml
换液频率	每周2~3次
生物安全等级	1
细胞背景
种属	人源
组织来源	血液
肿瘤类型	急性淋巴细胞白血病
供体信息	4岁高加索女性
背景描述	CRF-CEM细胞是一种通常用于免疫肿瘤学和免疫学研究的人类T淋巴母细胞。这些细胞是从一名患有急性淋巴细胞白血病（ALL）的4岁白人女性的外周血中分离出来的。
遗传背景
蛋白表达	p53 negative
同工酶	ADA， 1ES-D， 1G6PD， BGLO-I， 1PEP-D， 1PGD， CPGM1， 1PGM3， 0
基因表达	CD3; Homo sapiens， expressed ，CD5; Homo sapiens， expressedCD7; Homo sapiens， expressed， CD4; Homo sapiens， expressed
致瘤性	叙利亚仓鼠
抗原表达	CD3 B (37%)， CD4 (50%)， CD5 (95%)， CD7 (77%)
病毒	EBV ELISA: reverse transcriptase negative; PCR: EBV -， HBV -， HCV -， HIV-1 -， HIV-2 -， HTLV-1/2 -， MLV -， SMRV -negative
逆转录酶	阴性
核型	modal number = 47; range = 41 to 95.Fifty karyotypes showed no consistent loss or gain of particular chromosomes. Twenty-eight percent of the cells with 45 chromosomes were C-; 53% of all cells had an extra D and 35% had an extra F. Only N1 and N18 were not affected by gain or loss. No marker chromosomes noted.

STR鉴定

STR位点信息

STR鉴定图

Amelogenin	X
CSF1PO	9,10,11 (RCB=RCB1980) 10,11 (AddexBio=C0003001/32; ATCC=CCL-119; Cosmic-CLP=905952; KCLB=10119; PubMed=20922763) 10,11,12 (JCRB=IFO50412; JCRB=JCRB9023) 10,13 (ATCC=CRL-8436; CLS=300147; DSMZ=ACC-240) 11 (ECACC=85112105; JCRB=JCRB0033; PubMed=19372543)
D2S1338	23,24 (DSMZ=ACC-240) 24 (ATCC=CCL-119; PubMed=19372543; PubMed=20922763)
D3S1358	14,15 (CLS=300147; DSMZ=ACC-240; KCLB=10119) 15 (ATCC=CCL-119; PubMed=19372543) 15,16 (PubMed=20922763)
D5S818	12,13 (AddexBio=C0003001/32; ATCC=CCL-119; ATCC=CRL-8436; CLS=300147; DSMZ=ACC-240; ECACC=85112105; JCRB=IFO50412; JCRB=JCRB0033; JCRB=JCRB9023; KCLB=10119; PubMed=19372543; PubMed=20922763; RCB=RCB1980) 12,13,14 (Cosmic-CLP=905952)
D7S820	9,12 (JCRB=JCRB0033) 9,13 (AddexBio=C0003001/32; ATCC=CCL-119; ATCC=CRL-8436; CLS=300147; Cosmic-CLP=905952; DSMZ=ACC-240; ECACC=85112105; JCRB=IFO50412; JCRB=JCRB9023; KCLB=10119; PubMed=19372543; PubMed=20922763; RCB=RCB1980)
D8S1179	12,13 (CLS=300147; DSMZ=ACC-240; PubMed=20922763) 13 (ATCC=CCL-119; PubMed=19372543)
D13S317	10,11,12 (RCB=RCB1980) 11 (ATCC=CRL-8436; CLS=300147; DSMZ=ACC-240) 11,12 (AddexBio=C0003001/32; ATCC=CCL-119; Cosmic-CLP=905952; ECACC=85112105; JCRB=IFO50412; JCRB=JCRB0033; JCRB=JCRB9023; KCLB=10119; PubMed=19372543; PubMed=20922763)
D16S539	10,13 (AddexBio=C0003001/32; ATCC=CCL-119; ATCC=CRL-8436; CLS=300147; Cosmic-CLP=905952; DSMZ=ACC-240; ECACC=85112105; JCRB=IFO50412; JCRB=JCRB0033; JCRB=JCRB9023; PubMed=19372543; PubMed=20922763) 10,13,14 (RCB=RCB1980)
D18S51	13 (DSMZ=ACC-240) 13,18 (ATCC=CCL-119; CLS=300147)
D19S433	14,15
D21S11	30,33.2 (ATCC=CCL-119; PubMed=19372543; PubMed=20922763) 30,34.2 (CLS=300147; DSMZ=ACC-240)
FGA	22,23,24,25 (DSMZ=ACC-240) 23,24 (ATCC=CCL-119; CLS=300147; PubMed=20922763) 24 (PubMed=19372543)
Penta D	10,11 (CLS=300147; DSMZ=ACC-240) 11 (ATCC=CCL-119)
Penta E	5 (DSMZ=ACC-240) 5,14 (ATCC=CCL-119; CLS=300147)
TH01	6,7
TPOX	7,8 (DSMZ=ACC-240) 8 (AddexBio=C0003001/32; ATCC=CCL-119; ATCC=CRL-8436; CLS=300147; Cosmic-CLP=905952; ECACC=85112105; JCRB=IFO50412; JCRB=JCRB0033; JCRB=JCRB9023; KCLB=10119; PubMed=19372543; PubMed=20922763; RCB=RCB1980)
vWA	17,18,19 (DSMZ=ACC-240) 17,19 (AddexBio=C0003001/32; ATCC=CCL-119; ATCC=CRL-8436; CLS=300147; Cosmic-CLP=905952; ECACC=85112105; JCRB=IFO50412; JCRB=JCRB0033; JCRB=JCRB9023; KCLB=10119; PubMed=19372543; PubMed=20922763) 18,19 (RCB=RCB1980)